Orn-0829 hydrate
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Orn-0829 hydrate
- Structure (SMILES)
- C(=O)(c1c(ccc(c1)C)-n2nccn2)N3[C@H](Cn4nc(cc4)-c5ccc(cn5)F)OCCC3.O.C(=O)(c1c(ccc(c1)C)-n2nccn2)N3[C@H](Cn4nc(cc4)-c5ccc(cn5)F)OCCC3.C(=O)(c1c(ccc(c1)C)-n2nccn2)N3[C@H](Cn4nc(cc4)-c5ccc(cn5)F)OCCC3.C(=O)(c1c(ccc(c1)C)-n2nccn2)N3[C@H](Cn4nc(cc4)-c5ccc(cn5)F)OCCC3
- orn 0829 hydrate
- Orn-0829 hydrate
- ORN-0829 HYDRATE
- orn0829 hydrate
- ORN0829 HYDRATE
- ts 142
- Ts-142
- TS-142
- TS-142 10 mg
- TS-142 5 mg
- TS-142, 10 mg
- CAS registry numbers
- 2265899-50-9
- ChEMBL ID
- CHEMBL4650522
- InChIKey
- VFOCOQRYYZPTLV-RUCMDRKWSA-N
- PubChem compound IDs
- 154572855
- FDA ingredient codes (UNII)
- O67SLE6VA3
- First in class
- No
- Orphan designation
- No
- Mechanism
- Orexin receptor antagonist
- Action type
- Antagonist
- Target
- Orexin receptor
- Protein identifier
- O43613
- Mechanism
- Orexin receptor antagonist
- Action type
- Antagonist
- Target
- Orexin receptor
- Protein identifier
- O43614
Open Targets mechanisms
- Mechanism
- Orexin receptor antagonist
- Action type
- Antagonist
- Target
- Orexin receptor
- Condition
- Liver Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001421
- Subject identifier
- D008107
- Condition
- Sleep Apnea, Obstructive
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003918
- Subject identifier
- D020181
- Condition
- Sleep Initiation and Maintenance Disorders
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004698
- Subject identifier
- D007319
- Condition identifier
- EFO_0001421
- Highest recorded phase
- 1
- Condition identifier
- EFO_0003918
- Highest recorded phase
- 1
- Condition identifier
- EFO_0004698
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0013600
- Highest recorded phase
- 3
- NCT04469023
- NCT04573725
- NCT05453136
- NCT05461352
- NCT04746105
- NCT05624944
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Heavy atoms
- 133
- Monoisotopic mass
- 1806.73816921
- Natural product
- No
Related records
Trials (16)
- A Clinical Pharmacology Study of TS-142 in Patients with Obstructive Sleep Apnea Hypopnea.
- A Food Effect Study of TS-142 in Healthy Subjects
- A Pharmacokinetic Study of TS-142 in Patients with Hepatic Impairment
- A Phase I Study of TS-142 in Healthy Participants (Repeated Doses)
- A Phase I Study of TS-142 in Healthy Participants (Single Doses)
- A QT/QTc Evaluation Study of TS-142 in Healthy Adult Subjects
- A Single Ascending and Repeated Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TS-142 in Healthy Participants
- A Study to Evaluate Next Day Effects of TS-142 on Driving Performance in Healthy Subjects
- A Study to Investigate the Next-day Residual Effects of TS-142 in Healthy Elderly Subjects
- Drug-drug Interaction Study with TS-142 in Healthy Adult Subjects (concomitant Administration of Itraconazole)
- Early Phase 2 Clinical Study of TS-142 in Patients with Insomnia Disorder
- Late Phase II Study of TS-142 in Patients with Insomnia
- Long-Term Study of TS-142 in Patients with Insomnia
- Mass Balance Study of TS-142 in Healthy Adult Subjects.
- Phase III Study of TS-142 in Patients with Insomnia
- Safety, Pharmacokinetic, and Pharmacodynamic Study of TS-142 in Healthy Subjects
In development for (3)
- Insomnia Phase 3
- Liver disorder Phase 1
- Obstructive sleep apnea syndrome Phase 1